Avinger Inc: Nasdaq/NYSE listing notice — Avinger receives Nasdaq deficiency notice for bid price below $1 per share

Avinger Inc

Bid price of common stock below $1 for 30 consecutive business days as of April 25, 2023.
Company has 180 calendar days, until October 23, 2023, to regain compliance.
To regain compliance, bid price must close at $1 or more for at least ten consecutive business days.
If not cured, company may be eligible for additional 180-day period if it meets other listing standards.
Notice has no immediate effect on listing; company is monitoring and considering options including reverse stock split.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Avinger Inc received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

April 25, 2023, Avinger, Inc. (the “Company”), received a letter from the Listing Qualifications Department of The NASDAQ Stock Market, LLC (“Nasdaq”) notifying the Company that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2), as the minimum bid price for the Company’s listed securities was less than $1 for the previous 30 consecutive business days. The Company has a period of 180 calendar days, or until October 23, 2023, to regain compliance with the rule referred to in this paragraph. To regain compliance, the bid price of the Company’s common stock must close at $1 or

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001437749-23-011052

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.